Rather, the FDA suggested the creation of a model-new regulatory pathway that could contain safeguards such as a minimal authorized purchase age. But producing this type of pathway would call for an act of Congress — something not likely to occur shortly.Giving info on the precise specifications required to create a drug that may be derived from